Published in Int J Radiat Oncol Biol Phys on February 01, 2005
Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer. World J Gastroenterol (2009) 1.05
Treatment options in recurrent cervical cancer (Review). Oncol Lett (2010) 0.92
Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases. J Gynecol Oncol (2013) 0.87
The value of image-guided intensity-modulated radiotherapy in challenging clinical settings. Br J Radiol (2013) 0.79
Cancer of the pelvis: definitive three-dimensional conformal radiotherapy for patients with isolated recurrence in the para-aortic lymph nodes. J Radiat Res (2012) 0.79
Prolonged survival in a patient with isolated skull recurrence of cervical carcinoma - Case report and review of the literature. Gynecol Oncol Rep (2014) 0.75
Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation. Obstet Gynecol Sci (2016) 0.75
RapidArc for centrally recurrent cervical cancer in the vaginal cuff following primary surgical therapy: a case report. World J Surg Oncol (2016) 0.75
Salvage radiotherapy for lymph node recurrence after radical surgery in cervical cancer. J Gynecol Oncol (2012) 0.75
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol (2009) 5.37
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol (2004) 4.69
Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One (2008) 4.24
Notch-deficient skin induces a lethal systemic B-lymphoproliferative disorder by secreting TSLP, a sentinel for epidermal integrity. PLoS Biol (2008) 2.98
Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys (2002) 2.55
Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility. Gynecol Oncol (2007) 2.32
The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer (2007) 2.30
Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol (2005) 2.26
A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol (2009) 2.26
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res (2009) 2.23
Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA (2007) 2.22
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol (2007) 2.20
A microRNA expression signature for cervical cancer prognosis. Cancer Res (2010) 2.14
Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys (2003) 2.09
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol (2004) 2.08
Positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study. Mol Imaging Biol (2013) 2.05
Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study. J Clin Oncol (2014) 2.05
Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys (2009) 2.05
Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins. Gynecol Oncol (2013) 2.01
Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol (2007) 1.87
Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res (2008) 1.87
Progress toward a microradiation therapy small animal conformal irradiator. Med Phys (2006) 1.84
Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A (2003) 1.83
Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer (2014) 1.80
Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res (2008) 1.74
Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol (2002) 1.72
Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Cancer (2005) 1.68
Retrorectal tumors: a diagnostic and therapeutic challenge. Dis Colon Rectum (2005) 1.65
Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA (2009) 1.60
Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol (2009) 1.59
Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer? Gynecol Oncol (2002) 1.57
Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers. Clin Cancer Res (2011) 1.57
Diagnosis and treatment of gestational trophoblastic disease: ACOG Practice Bulletin No. 53. Gynecol Oncol (2004) 1.57
Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet (2004) 1.57
Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol (2010) 1.55
A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol (2007) 1.53
Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst (2013) 1.52
Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med (2008) 1.51
Magnitude of interfractional vaginal cuff movement: implications for external irradiation. Int J Radiat Oncol Biol Phys (2011) 1.46
FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One (2012) 1.45
Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy. Gynecol Oncol (2005) 1.45
Evidence for heritable predisposition to epigenetic silencing of MLH1. Int J Cancer (2007) 1.43
Adequate staging for uterine cancer can be performed through Pfannenstiel incisions. Gynecol Oncol (2003) 1.41
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol (2006) 1.41
Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. Int J Radiat Oncol Biol Phys (2005) 1.39
Discussion: 'Accuracy of preoperative endometrial sampling' by Huang et al. Am J Obstet Gynecol (2007) 1.38
Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy. Cancer (2007) 1.38
Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res (2003) 1.36
Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum (2008) 1.35
Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol (2011) 1.34
Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol (2005) 1.31
Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol (2002) 1.31
Temporal analysis of intratumoral metabolic heterogeneity characterized by textural features in cervical cancer. Eur J Nucl Med Mol Imaging (2013) 1.26
Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing. Nucleic Acids Res (2009) 1.26
ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. J Clin Oncol (2009) 1.25
Dosimetric effects of air pockets around high-dose rate brachytherapy vaginal cylinders. Int J Radiat Oncol Biol Phys (2010) 1.21
Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer (2005) 1.20
Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer (2010) 1.19
An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med (2008) 1.18
Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res (2007) 1.17
Epithelial ovarian cancer. J Natl Compr Canc Netw (2011) 1.16
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol (2004) 1.15